BioSpace News Archive

Ultrasound sensor specialist Novosound has signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, to develop technology aimed at advancing intravascular imaging.

AEON Biopharma, Inc. today announced the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine.

KemPharm, Inc. today announced the initiation of a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks’ zanidatamab.

A poster presented at the recent ESMO Immuno-Oncology Congress in Geneva demonstrates that the cResponse platform can be applied for the modeling and evaluation of immune modulating drugs in cancer tissue.

Lexaria Bioscience Corp. is pleased to announce it has demonstrated superior cannabidiol (“CBD”) blood absorption levels from its patented DehydraTECH-CBD™ relative to those of published, pharmaceutical-grade CBD industry comparators in its recently completed, multi-week human clinical hypertension study HYPER-H21-4.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide a summary of activities and accomplishments achieved during 2022 as outlined below.

The global plasma derived therapy market size was exhibited at USD 19.54 billion in 2022 and it is expected to hold around USD 33.75 billion by 2030, growing at a CAGR of 7.07% from 2022 to 2030.

Curium, the world’s leading nuclear medicine company, announced that with the successful restarting of the BR2 research reactor in Belgium on 20 December, Curium’s supply of molybdenum-99 and iodine-131 is continuing as usual.

Dimension led the round with multiple new institutional investors and significant participation from current investors; Silicon Valley Bank provided the debt facility.